Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.
复制标题
DOI：
10.1002/ijc.28384
复制
发表时间：
2014-06-01
影响因子：
6.4
通讯作者：
Sturgeon, C.
中科院分区：
文献类型：
--
作者：
Duffy, M. J.;Lamerz, R.;Haglund, C.;Nicolini, A.;Kalousova, M.;Holubec, L.;Sturgeon, C.
生物标志物目前在几种不同类型的胃肠道癌患者的检测和管理中发挥着重要作用，特别是结直肠癌、胃癌、胃食管交界处（GOJ）腺癌和胃肠道间质瘤（GIST）。本文的目的是提供最新的和循证的指南，在不同的胃肠道恶性肿瘤的生物标志物的使用。推荐的结直肠癌生物标志物包括在筛查年龄≥50岁的无症状受试者的肿瘤形成时进行的基于免疫化学的粪便潜血试验，在II期和III期患者的术后监测中进行的系列CEA水平，这些患者可能是发生远处转移时手术切除或全身治疗的候选者，K-RAS突变状态用于识别可能从抗EGFR治疗性抗体和微卫星不稳定性检测中获益的晚期疾病患者，作为Lynch综合征受试者的一线筛查。在晚期胃癌或GOJ癌症中，建议在选择曲妥珠单抗治疗患者时测量HER 2。对于疑似GIST的患者，KIT蛋白的测定应用作诊断辅助，而KIT突变分析可用于诊断GIST患者的治疗计划。
Biomarkers currently play an important role in the detection and management of patients with several different types of gastrointestinal cancer, especially colorectal, gastric, gastro-oesophageal junction (GOJ) adenocarcinomas and gastrointestinal stromal tumors (GISTs). The aim of this article is to provide updated and evidence-based guidelines for the use of biomarkers in the different gastrointestinal malignancies. Recommended biomarkers for colorectal cancer include an immunochemical-based fecal occult blood test in screening asymptomatic subjects ≥50 years of age for neoplasia, serial CEA levels in postoperative surveillance of stage II and III patients who may be candidates for surgical resection or systemic therapy in the event of distant metastasis occurring, K-RAS mutation status for identifying patients with advanced disease likely to benefit from anti-EGFR therapeutic antibodies and microsatellite instability testing as a first-line screen for subjects with Lynch syndrome. In advanced gastric or GOJ cancers, measurement of HER2 is recommended in selecting patients for treatment with trastuzumab. For patients with suspected GIST, determination of KIT protein should be used as a diagnostic aid, while KIT mutational analysis may be used for treatment planning in patients with diagnosed GISTs.
登录
查看更多内容
影响因子：
29.4
作者：
Boland CR;Goel A
通讯作者：
Goel A
影响因子：
8.4
作者：
Bokemeyer, Carsten;Van Cutsem, Eric;Koehne, Claus-Henning
通讯作者：
Koehne, Claus-Henning
影响因子：
3.5
作者：
Ailawadhi, S;Sunga, A;Fakih, M
通讯作者：
Fakih, M
影响因子：
45.3
作者：
Blanke, Charles D.;Rankin, Cathryn;Borden, Ernest C.
通讯作者：
Borden, Ernest C.
影响因子：
4.5
作者：
Berger, Barry M.;Ahlquist, David A.
通讯作者：
Ahlquist, David A.